drugset / Trial / NCT00319553

Post-licensure, Modified Double-blind, Multi-center Study Evaluating Safety and Immunogenicity of ADACEL® and BOOSTRIX®

NCT00319553

Phase 4 Completed 647 enrolled Sanofi
RandomizedParallel-groupQuadruple-blindPrevention

Summary

This is a descriptive study to evaluate the safety and immunogenicity of ADACEL® and BOOSTRIX® vaccines among US adolescents.

Timeline

Start
2006-05
Primary completion
2008-10
Completion
2008-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Adacel Vaccine 0.5 ml Intramuscular
Comparator Boostrix Vaccine 0.5 ml Intramuscular